Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8137370 | 0.84 | — | — | |
| SCHEMBL29005950 | 0.82 | FNTA (0.36) | EPHX1MAPTCA12CA1CA7 | |
| SCHEMBL10357924 | 0.78 | NPSR1 (0.32) | MAPTNPSR1PAOX | |
| SCHEMBL27925584 | 0.78 | PAOX (0.35) | NPSR1PAOX | |
| Hydrochloric Acid SCHEMBL27567194 | 0.76 | MAPT (0.33) | MAPT | |
| SCHEMBL10375145 | 0.75 | FNTA (0.40) | CA1CA7NPSR1PAOX | |
| SCHEMBL10969272 | 0.75 | FNTA (0.40) | CA1CA7NPSR1PAOX | |
| SCHEMBL2534109 | 0.75 | FNTA (0.40) | CA1CA7NPSR1PAOX | |
| SCHEMBL31461434 | 0.75 | CYP2D6 (0.35) | MAPTCA12CA1CA7CA14 | |
| Hydrochloric Acid SCHEMBL6428582 | 0.74 | MAPT (0.33) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114220937-B | Bipolar molecular stable perovskite material and photoelectric device | 浙江大学 | 2023-08-29 | — | — | CN | claimed |
| CN-116159445-A | Polyamide composite membrane and preparation method and application thereof | 万华化学集团股份有限公司 | 2023-05-26 | — | — | CN | claimed |
| CN-114220937-A | Bipolar molecular stable perovskite material and photoelectric device | 浙江大学 | 2022-03-22 | — | — | CN | claimed |
| CN-113382767-B | Urea compounds having substituents | 第一三共株式会社 | 2024-12-24 | — | — | CN | disclosed |
| CN-111251500-B | Foaming polymer particles with skin dilatancy and preparation method thereof | 厦门天策材料科技有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-117897382-A | Nitrogen-containing tricyclic compounds and pharmaceutical uses thereof | 日本烟草产业株式会社 | 2024-04-16 | — | — | CN | disclosed |
| CN-117693503-A | Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-112867721-B | STING agonistic compounds | 小野药品工业株式会社 | 2023-12-08 | — | — | CN | disclosed |
| CN-116970029-A | Bridged ring compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116925174-A | Urea compound, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-20230331700-A1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-10-19 | — | — | US | disclosed |
| US-5998471-A | SKIN DISORDERS; ANTIINFLAMMATORY AGENTS | ALLERGAN SALES, INC. (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1999043285-A2 | SULPHONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1999-09-02 | — | — | WO | disclosed |
| EP-0863755-A4 | ANTITHROMBOTIC DIAMINES | LILLY CO ELI (US) | 1999-01-20 | — | — | EP | disclosed |
| EP-0863755-A1 | ANTITHROMBOTIC DIAMINES | ELI LILLY AND COMPANY (US) | 1998-09-16 | — | — | EP | disclosed |
| US-5808083-A | Acetylenes disubstituted with a 5 alkyl, aryl or heteroaryl substituted dihydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity | ALLERGAN (US) | 1998-09-15 | — | — | US | disclosed |
| EP-0800517-A1 | ACETYLENES DISUBSTITUTED WITH A 5 OR 8 SUBSTITUTED TETRAHYDRONAPHTHYL OR DIHYDRONAPHTHYL GROUP AND WITH AN ARYL OR HETEROARYL GROUPS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | Allergan (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1997025033-A1 | ANTITHROMBOTIC DIAMINES | ELI LILLY AND COMPANY (US) | 1997-07-17 | — | — | WO | disclosed |
| US-5648514-A | Substituted acetylenes having retinoid-like biological activity | ALLERGAN (US) | 1997-07-15 | — | — | US | disclosed |
| WO-1996020930-A1 | ACETYLENES DISUBSTITUTED WITH A 5 OR 8 SUBSTITUTED TETRAHYDRONAPHTHYL OR DIHYDRONAPHTHYL GROUP AND WITH AN ARYL OR HETEROARYL GROUPS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1996-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331700-A1 | COMPOUND HAVING CYCLIC STRUCTURE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B | EPHX1 237/4885MAPT 3883/4885CA12 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.